معرفی
Clifford Berkman is a Professor in the Department of Chemistry at Washington State University (WSU). He holds a Ph.D. in Chemistry from Loyola University of Chicago (1993) and a B.A. in Chemistry from Lake Forest College (1986). His research focuses on designing protease inhibitors targeting cancer, particularly prostate-specific membrane antigen (PSMA), with applications in diagnostic imaging and therapeutic drug development. His work has led to the creation of Cancer Targeted Technology (CTT), a startup advancing PSMA-based clinical trials for cancer treatments. Key contributions include PSMA-targeted radiopharmaceuticals, controlled-release prodrugs, and exosome-based diagnostic tools. Recent studies involve developing 18F-labeled PET imaging agents and Lu-177-labeled therapeutics for prostate cancer. Awards and grants are not explicitly listed in the provided materials.
Education:
- Ph.D. Chemistry, Loyola University of Chicago, 1993
- B.A. Chemistry, Lake Forest College, 1986
Research interests span cancer drug design, enzyme inhibition mechanisms, and translational medicine. His lab pioneered PSMA inhibitors for prostate cancer imaging and therapy, with notable advancements in targeted photodynamic therapy and exosome-based biomarkers. Collaborations include preclinical studies on radionuclide therapies and clinical trials for PET imaging agents like CTT1057.
Publications emphasize PSMA biology, drug delivery systems, and prostate cancer therapeutics. His work bridges organic synthesis, enzymology, and clinical applications, reflecting a commitment to translational oncology research.
Advancing therapies via CTT highlights his focus on real-world medical impact, while ongoing studies explore pH-sensitive linkers for controlled drug release and novel antibacterial agents targeting tuberculosis.
